[go: up one dir, main page]

SG11201404677TA - Process of expanding t cells - Google Patents

Process of expanding t cells

Info

Publication number
SG11201404677TA
SG11201404677TA SG11201404677TA SG11201404677TA SG11201404677TA SG 11201404677T A SG11201404677T A SG 11201404677TA SG 11201404677T A SG11201404677T A SG 11201404677TA SG 11201404677T A SG11201404677T A SG 11201404677TA SG 11201404677T A SG11201404677T A SG 11201404677TA
Authority
SG
Singapore
Prior art keywords
expanding
cells
Prior art date
Application number
SG11201404677TA
Inventor
Cliona M Rooney
Ann M Leen
Juan F Vera
Minhtran V Ngo
Rainer Ludwig Knaus
Original Assignee
Cell Medica Ltd
Baylor College Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46146968&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201404677T(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cell Medica Ltd, Baylor College Medicine filed Critical Cell Medica Ltd
Publication of SG11201404677TA publication Critical patent/SG11201404677TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2304—Interleukin-4 (IL-4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1121—Dendritic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SG11201404677TA 2011-12-12 2012-04-23 Process of expanding t cells SG11201404677TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161569577P 2011-12-12 2011-12-12
PCT/GB2012/050896 WO2013088114A1 (en) 2011-12-12 2012-04-23 Process of expanding t cells

Publications (1)

Publication Number Publication Date
SG11201404677TA true SG11201404677TA (en) 2014-11-27

Family

ID=46146968

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201404677TA SG11201404677TA (en) 2011-12-12 2012-04-23 Process of expanding t cells

Country Status (9)

Country Link
US (2) US10351824B2 (en)
EP (1) EP2791322A1 (en)
JP (3) JP6081483B2 (en)
KR (1) KR101749195B1 (en)
CN (3) CN109182266A (en)
AU (1) AU2012351347B2 (en)
BR (1) BR112014014591A8 (en)
SG (1) SG11201404677TA (en)
WO (1) WO2013088114A1 (en)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011028531A1 (en) 2009-08-24 2011-03-10 Baylor College Of Medicine Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses
GB201121308D0 (en) 2011-12-12 2012-01-25 Cell Medica Ltd Process
BR112014014591A8 (en) * 2011-12-12 2017-07-04 Baylor College Medicine process for the in vitro expansion of antigen-specific t cells, expanded autologous or allogeneic t-cell product, pharmaceutical composition, and method of treatment of a patient, and uses of an engineered cell line, mixed pulsed dendritic cells antigen-peptide, t-apcs pulsed with antigen-peptide / peptide mixtures, and antigen-peptide mixtures with pbmcs
PT2812431T (en) 2012-02-09 2019-10-18 Baylor College Medicine PEPMIXES TO GENERATE MULTIVIRAL CTLS WITH WIDE SPECIFICITY
JP2015519080A (en) * 2012-06-11 2015-07-09 ウィルソン ウォルフ マニュファクチャリング コーポレイションＷｉｌｓｏｎ Ｗｏｌｆ Ｍａｎｕｆａｃｔｕｒｉｎｇ Ｃｏｒｐｏｒａｔｉｏｎ Improved cell culture method for adoptive cell therapy
JP6599450B2 (en) * 2014-10-02 2019-10-30 アメリカ合衆国 Method for isolating T cells having antigen specificity for a cancer specific mutation
US10046047B2 (en) * 2015-02-06 2018-08-14 Heat Biologics, Inc. Vector co-expressing vaccine and costimulatory molecules
US12478670B2 (en) 2015-03-20 2025-11-25 Children's National Medical Center Generating HPV antigen-specific T cells from a naïve T cell population
IL294055A (en) * 2015-03-20 2022-08-01 Childrens Nat Medical Ct Production of t-cells specific for a virus antigen or other antigen from a population of naïve t-cells
WO2017075571A1 (en) 2015-10-30 2017-05-04 Children's National Medical Center Generating hpv antigen-specific cells from a naive t cell population
CN104830793A (en) * 2015-05-05 2015-08-12 杨光华 DC cell based on LMP-1 antigen, targeting immune cell population, preparation method and applications thereof
WO2017023803A1 (en) 2015-07-31 2017-02-09 Regents Of The University Of Minnesota Modified cells and methods of therapy
SG10202112047TA (en) 2015-09-18 2021-12-30 Baylor College Medicine Immunogenic antigen identification from a pathogen and correlation to clinical efficacy
CN108138171B (en) * 2015-10-08 2022-05-13 国立大学法人名古屋大学 Method for preparing gene modified T cell for expressing chimeric antigen receptor
ITUB20154769A1 (en) * 2015-11-04 2017-05-04 Centro Di Riferimento Oncologico Cro Irccs Aviano Anti-BARF1 monoclonal antibody
EP3430131B1 (en) * 2016-03-17 2022-06-08 Berkeley Lights, Inc. Selection and cloning of t lymphocytes in a microfluidic device
WO2017197347A1 (en) * 2016-05-12 2017-11-16 Adicet Bio, Inc. METHODS FOR SELECTIVE EXPANSION OF γδ T-CELL POPULATIONS AND COMPOSITIONS THEREOF
US10052372B2 (en) * 2016-05-24 2018-08-21 Tessa Therapeutics Pte Ltd T cell expansion
KR20190028662A (en) 2016-05-25 2019-03-19 더 카운실 오브 더 퀸즐랜드 인스티튜트 오브 메디컬 리서치 Methods of immunotherapy
KR20190028664A (en) * 2016-05-25 2019-03-19 더 카운실 오브 더 퀸즐랜드 인스티튜트 오브 메디컬 리서치 Immune checkpoint inhibitors and cytotoxic T cells for the treatment of cancer
SG11201809534UA (en) * 2016-05-25 2018-12-28 Council Queensland Inst Medical Res Methods of treating autoimmune disease using allogeneic t cells
US11472856B2 (en) 2016-06-13 2022-10-18 Torque Therapeutics, Inc. Methods and compositions for promoting immune cell function
US11549090B2 (en) * 2016-08-21 2023-01-10 Adva Biotechnology Ltd. Bioreactor and methods of use thereof
US9642906B2 (en) * 2016-09-16 2017-05-09 Baylor College Of Medicine Generation of HPV-specific T-cells
AU2017326173B2 (en) * 2016-09-16 2022-08-18 Baylor College Of Medicine Platform for activation and expansion of virus-specific T-cells
BR112019014406A2 (en) 2017-01-20 2020-04-28 Atara Biotherapeutics Inc methods of treating multiple sclerosis using autologous t cells
WO2018206794A1 (en) * 2017-05-11 2018-11-15 Servicio Andaluz De Salud Diagnostic and therapeutic uses of an in vitro system of autologous lymphocytes culture
WO2019031939A2 (en) * 2017-08-10 2019-02-14 주식회사 굳티셀 Method for activating t cells for cancer treatment
JP7285828B2 (en) 2017-09-05 2023-06-02 トルク セラピューティクス， インコーポレイテッド Therapeutic protein compositions and methods of making and using them
US20200338125A1 (en) * 2017-11-06 2020-10-29 Ludwig Institute For Cancer Research Ltd Method for expansion of lymphocytes
EP3784696A1 (en) 2018-04-23 2021-03-03 Baylor College Of Medicine Chimeric hla accessory receptor
WO2019222763A1 (en) * 2018-05-18 2019-11-21 Children's National Medical Center System of cell expansion and methods of using the same
WO2019239216A2 (en) * 2018-06-13 2019-12-19 The Council Of The Queensland Institute Of Medical Research Viral detection assay
ES3000183T3 (en) 2018-09-10 2025-02-27 Atara Biotherapeutics Inc Methods for expanding antigen-specific car-t cells, compositions and uses related thereto
WO2020069377A1 (en) * 2018-09-27 2020-04-02 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods of using lysine deacetylase (kdac) inhibition to generate antigen specific memory t cell responses for durable immunotherapy
WO2020077200A1 (en) * 2018-10-12 2020-04-16 Georgia Tech Research Corporation Methods and systems for dynamic predictive modeling and control of inflammation
CA3118757A1 (en) 2018-11-08 2020-05-14 Neximmune, Inc. T cell compositions with improved phenotypic properties
US20200199567A1 (en) * 2018-12-20 2020-06-25 Medimmune, Llc Methods for selection and expansion of t cells expressing pd-1
CN113597430A (en) * 2019-02-08 2021-11-02 古德T细胞有限公司 Methods of activating T cells for cancer treatment
BR112021019669A2 (en) 2019-04-12 2021-12-07 C4 Therapeutics Inc Compound, pharmaceutical composition, method of treating a disorder, compound for use in the production of a medicine, and, use of a compound in treating a disorder
GB201911066D0 (en) 2019-08-02 2019-09-18 Achilles Therapeutics Ltd T cell therapy
CN110646619A (en) * 2019-09-25 2020-01-03 格源致善(上海)生物科技有限公司 Method for detecting cell factor secreted by specific T cell in lung cancer or intestinal cancer
JP7340144B2 (en) * 2019-10-02 2023-09-07 アメリカ合衆国 Method for isolating T cells with antigenic specificity for cancer-specific mutations
JP6878544B2 (en) * 2019-10-02 2021-05-26 アメリカ合衆国 A method for isolating T cells that have antigen specificity for cancer-specific mutations
CN110964698B (en) * 2019-12-25 2022-05-10 杭州中赢生物医疗科技有限公司 Artificial antigen presenting cell and preparation method and application thereof
CN115485385A (en) 2020-03-04 2022-12-16 瑞泽恩制药公司 Methods and compositions for sensitizing tumor cells to immunotherapy
JP2020143057A (en) * 2020-04-01 2020-09-10 アメリカ合衆国 Methods for isolating t cell receptors having antigen specificity to cancer specific mutations
WO2021221927A1 (en) 2020-04-27 2021-11-04 Parsons Corporation Narrowband iq signal obfuscation
KR20230002554A (en) 2020-04-28 2023-01-05 아킬레스 테라퓨틱스 유케이 리미티드 T cell therapy
CN111856020B (en) * 2020-06-19 2022-09-27 南方医科大学南方医院 Hepatitis B Virus (HBV) specific T cell detection method and application thereof
GB202109886D0 (en) 2021-07-08 2021-08-25 Achilles Therapeutics Uk Ltd Assay
WO2022214835A1 (en) 2021-04-09 2022-10-13 Achilles Therapeutics Uk Limited Batch release assay for pharmaceutical products relating to t cell therapies
CN117529551A (en) 2021-04-27 2024-02-06 贝勒医学院 Virus-specific immune cells expressing chimeric antigen receptors
JP2024524185A (en) 2021-06-22 2024-07-05 アキレス セラピューティクス ユーケー リミテッド Methods for generating antigen-specific T cells
TW202340455A (en) * 2021-11-23 2023-10-16 美國貝勒醫學院 Improved virus-specific t cell
CA3251962A1 (en) * 2022-02-15 2023-08-24 Marker Therapeutics, Inc. Compositions and methods for antigen-specific t cell expansion
AU2023254191A1 (en) 2022-04-11 2024-10-17 Regeneron Pharmaceuticals, Inc. Compositions and methods for universal tumor cell killing
WO2023198744A1 (en) 2022-04-13 2023-10-19 Tessa Therapeutics Ltd. Therapeutic t cell product
EP4536252A4 (en) * 2022-06-08 2025-12-24 Sheba Impact Ltd VIRUS-SPECIFIC RECOMBINANT T-CELL RECEPTORS AND T-CELLS WITH THAT
WO2023238124A1 (en) * 2022-06-08 2023-12-14 Sheba Impact Ltd. Virus-specific t cells, methods of their preparation and use thereof
KR20240104693A (en) * 2022-12-28 2024-07-05 서울대학교산학협력단 Method for inducing proliferation of antigen-specific T-cells

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US550246A (en) 1895-11-26 Nut-lock
WO1994002156A1 (en) 1992-07-16 1994-02-03 The Board Of Trustees Of Leland Stanford Junior University Methods for using dendritic cells to activate t cells
US6821778B1 (en) 1993-12-01 2004-11-23 The Board Of Trustees Of Leland Stanford Junior University Methods for using dendritic cells to activate gamma/delta-T cell receptor-positive T cells
AUPM446594A0 (en) 1994-03-16 1994-04-14 Csl Limited Cytotoxic t-cell epitopes identified within epstein-barr virus
NZ266264A (en) 1994-04-06 1997-01-29 Immunex Corp Mammalian epithelium-derived t-cell factor called interleukin-15
US6300090B1 (en) 1994-07-29 2001-10-09 The Rockefeller University Methods of use of viral vectors to deliver antigen to dendritic cells
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
EP0747481B1 (en) 1995-06-06 2001-12-19 Organon Teknika B.V. Epstein-Barr virus peptides and antibodies against these peptides
FR2745185B1 (en) 1996-02-28 1998-05-15 Sanofi Sa USE OF IL-7 IN THE TREATMENT OF AUTOIMMUNE DISEASES, PARTICULARLY INSULIN-DEPENDENT DIABETES MELLITUS
US6703024B2 (en) 1996-05-24 2004-03-09 The Council Of The Queensland Institute Of Medical Research EBV CTL epitopes
US5962318A (en) * 1996-11-15 1999-10-05 St. Jude Children's Research Hospital Cytotoxic T lymphocyte-mediated immunotherapy
CA2278189A1 (en) 1997-01-31 1998-08-06 Epimmune, Inc. Peptides and peptide-loaded antigen presenting cells for the activation of ctl
US6528307B1 (en) 1997-04-25 2003-03-04 The Wistar Institute Of Anatomy And Biology Cytolytic T-cell clones against colorectal carcinoma
AUPO784197A0 (en) 1997-07-10 1997-08-07 Csl Limited Treatment of nasopharyngeal carcinoma
EP0922758B1 (en) 1997-10-27 2009-04-15 Rockefeller University Methods and compositions for obtaining mature dendritic cells
US20020155108A1 (en) 1998-05-04 2002-10-24 Biocrystal, Ltd. Method for ex vivo loading of antigen presenting cells with antigen, and a vaccine comprising the loaded cells
US6828147B1 (en) 1999-02-24 2004-12-07 The Wistar Institute Of Anatomy And Biology Method of modifying cytotoxic cells and uses thereof
US7005131B1 (en) 1999-08-13 2006-02-28 The Rockefeller University Protective antigen of Epstein Barr Virus
DE10009341A1 (en) 2000-02-22 2001-09-06 Florian Kern Method for antigen-specific stimulation of T lymphocytes
US20020164331A1 (en) 2000-06-19 2002-11-07 Exley Mark A. Compositions and methods of monoclonal and polyclonal antibodies specific for T cell subpopulations
WO2002022648A2 (en) 2000-09-15 2002-03-21 Ortho-Mcneil Pharmaceutical, Inc. Compositions and methods for inducing specific cytolytic t cell responses
EP1229043A1 (en) 2001-01-30 2002-08-07 Cyto-Barr B.V. Peptides derived from Epstein Barr virus (EBV) proteins LMP1, LMP2 and BARF1 antibody reagents reactive therewith
EP1444330A1 (en) 2001-11-07 2004-08-11 Kirin Beer Kabushiki Kaisha Expansion of t cells in vitro and expanded t cell populations
US20030148982A1 (en) 2001-11-13 2003-08-07 Brenner Malcolm K. Bi-spcific chimeric T cells
US20040096457A1 (en) 2001-12-11 2004-05-20 Huber Brigitte T Treatment and prevention of ebv infection and ebv-associated disorders
AU2003202908A1 (en) 2002-01-03 2003-07-24 The Trustees Of The University Of Pennsylvania Activation and expansion of t-cells using an engineered multivalent signaling platform
US7745140B2 (en) 2002-01-03 2010-06-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
GB0214528D0 (en) * 2002-06-24 2002-08-07 Univ Aberdeen Materials and methods for induction of immune tolerance
US20070048329A1 (en) 2002-11-07 2007-03-01 Rajiv Khanna Epstein barr virus peptide epitopes, polyepitopes and delivery system therefor
AU2002953238A0 (en) 2002-12-09 2003-01-02 The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland In vitro immunization
ZA200507562B (en) * 2003-03-26 2006-11-29 Cytos Biotechnology Ag HIV-peptide-carrier-conjugates
JP2007511205A (en) 2003-10-08 2007-05-10 ウィルソン ウォルフ マニュファクチャリング コーポレイション Method and apparatus for culturing cells using gas permeable substances
US20050221481A1 (en) 2004-03-30 2005-10-06 Istituto Superiore Di Sanita' Amplification of T cells from human cord blood in serum-deprived culture stimulated with stem cell factor, interleukin-7 and interleukin-2
TWI382843B (en) * 2004-10-07 2013-01-21 Argos Therapeutics Inc Mature dendritic cell compositions and methods for culturing same
WO2006099448A2 (en) 2005-03-14 2006-09-21 University Of Iowa Research Foundation Accelerated cd8+ t-cell memory after dendritic cell vaccination
EP1712615A1 (en) 2005-04-15 2006-10-18 Txcell In vitro production of a cell population using feeder cells
AU2006247802A1 (en) 2005-05-11 2006-11-23 The Trustees Of The University Of Pennsylvania Methods for the rapid expansion of antigen specific T-cells
US20100035282A1 (en) 2005-08-03 2010-02-11 Maria Chiara Bonini Use of common gamma chain cytokines for the visualization, isolation and genetic modification of memory t lymphocytes
JP4824389B2 (en) 2005-10-28 2011-11-30 株式会社医学生物学研究所 Cytotoxic T cell epitope peptide that specifically attacks Epstein-Barr virus infected cells and uses thereof
US20070196389A1 (en) * 2005-11-18 2007-08-23 The Ohio State University Research Foundation Viral gene products and methods for vaccination to prevent viral associated diseases
WO2008025992A2 (en) 2006-09-01 2008-03-06 Cambridge Enterprise Limited Methods of expanding non-effector cd8 t-cell populations
US7846446B2 (en) 2006-11-22 2010-12-07 Board Of Trustees Of The University Of Arkansas Multi-epitope peptide-loaded dendritic cell immunotherapy for cancer
MX2009008140A (en) * 2007-02-02 2009-10-26 Baylor Res Inst Vaccines based on targeting antigen to dcir expressed an antigen-presenting cells.
EP2205252B1 (en) 2007-09-27 2017-04-05 The Board Of Trustees Of The University Of Arkansas Inhibition of dendritic cell-driven regulatory t cell activation and potentiation of tumor antigen-specific t cell responses by interleukin-15 and map kinase inhibitor
EP2207875A1 (en) 2007-10-24 2010-07-21 Anne Letsch Antigen-specific t-cell preparations from bone marrow
EP2065462A1 (en) 2007-11-27 2009-06-03 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Ex vivo method for producing a preparation containing CD4+ T cells specific for EBV structural antigens
JP2011505144A (en) * 2007-11-30 2011-02-24 ベイラー カレッジ オブ メディシン Dendritic cell vaccine composition and use thereof
US20090324630A1 (en) * 2008-04-21 2009-12-31 Jensen Michael C Fusion multiviral chimeric antigen
JP2012508561A (en) 2008-09-11 2012-04-12 ユニバーシティ オブ フロリダ リサーチファウンデーション インコーポレイティッド System and method for producing T cells
CN101824400B (en) 2009-03-05 2012-08-08 中国科学院微生物研究所 Method for amplifying and multiplying T cells with antigenic specificity
WO2011028531A1 (en) * 2009-08-24 2011-03-10 Baylor College Of Medicine Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses
JP5833443B2 (en) 2009-08-29 2015-12-16 株式会社バイオメッドコア Method for measuring antigen-specific T cell inducibility
GB0917090D0 (en) 2009-09-29 2009-11-11 Ucl Biomedica Plc T-cell receptor
US20130115617A1 (en) 2009-12-08 2013-05-09 John R. Wilson Methods of cell culture for adoptive cell therapy
US8956860B2 (en) 2009-12-08 2015-02-17 Juan F. Vera Methods of cell culture for adoptive cell therapy
EP2698430A3 (en) 2009-12-08 2014-03-05 Wilson Wolf Manufacturing Corporation Methods of cell culture for adoptive cell therapy
US9114100B2 (en) 2010-05-17 2015-08-25 Duke University Methods of treatment using ex vivo expansion of cord blood T cells
EP2600890A1 (en) 2010-08-04 2013-06-12 Instituto Europeo di Oncologia S.r.l. Method of antigen loading for immunotherapy
WO2012054792A2 (en) 2010-10-22 2012-04-26 Virginia Commonwealth University Composition and method for immunological treatment of cancer, prevention of cancer recurrence and metastasis, and overcoming immune suppressor cells
US20130045491A1 (en) 2011-07-19 2013-02-21 Derya Unutmaz Methods for activating t cells
RU2636503C2 (en) 2011-09-08 2017-11-23 Иеда Рисеч Энд Девелопмент Ко. Лтд. Central memory t-cells of against third party, methods for their production and their application in transplantation and diseases treatment
BR112014014591A8 (en) * 2011-12-12 2017-07-04 Baylor College Medicine process for the in vitro expansion of antigen-specific t cells, expanded autologous or allogeneic t-cell product, pharmaceutical composition, and method of treatment of a patient, and uses of an engineered cell line, mixed pulsed dendritic cells antigen-peptide, t-apcs pulsed with antigen-peptide / peptide mixtures, and antigen-peptide mixtures with pbmcs
PT2812431T (en) 2012-02-09 2019-10-18 Baylor College Medicine PEPMIXES TO GENERATE MULTIVIRAL CTLS WITH WIDE SPECIFICITY
US20130217122A1 (en) 2012-02-21 2013-08-22 The Trustees Of The University Of Pennsylvania Expansion of Interferon-Gamma-Producing T-Cells Using Glypican-3 Peptide Library
CN104428411B (en) 2012-05-08 2018-11-23 健康科学西部大学 Standardized ex vivo platform for antigen-specific expansion of CD4+ T cell populations

Also Published As

Publication number Publication date
CN104769104A (en) 2015-07-08
JP2017038621A (en) 2017-02-23
KR20140123489A (en) 2014-10-22
US20150017723A1 (en) 2015-01-15
BR112014014591A8 (en) 2017-07-04
CN110241080A (en) 2019-09-17
US11155784B2 (en) 2021-10-26
BR112014014591A2 (en) 2017-06-13
KR101749195B1 (en) 2017-06-20
US10351824B2 (en) 2019-07-16
EP2791322A1 (en) 2014-10-22
AU2012351347B2 (en) 2016-05-19
JP2015501651A (en) 2015-01-19
WO2013088114A1 (en) 2013-06-20
JP2020054348A (en) 2020-04-09
JP6081483B2 (en) 2017-02-15
CN109182266A (en) 2019-01-11
US20190270966A1 (en) 2019-09-05
AU2012351347A1 (en) 2014-08-07

Similar Documents

Publication Publication Date Title
SG11201404677TA (en) Process of expanding t cells
EP2729561A4 (en) Cell culture process
GB201121308D0 (en) Process
GB201103499D0 (en) Process
GB201107072D0 (en) Process
GB201110042D0 (en) Growth of cells
PL2793599T3 (en) Process
GB201218123D0 (en) Process
IL228546A0 (en) Fermentation process
GB201101370D0 (en) Process
GB201121557D0 (en) Process
GB201112051D0 (en) Process
GB201107073D0 (en) Process
IL229126A0 (en) Process
GB201218121D0 (en) Process
GB201218124D0 (en) Process
PT2726454T (en) Process
GB201112370D0 (en) Process
GB201103092D0 (en) Process
GB201105537D0 (en) New process
GB201107221D0 (en) Process
GB201119607D0 (en) Method of manufacture
SG11201403684YA (en) Process
HK1197426A (en) Process of expanding t cells
GB2493491B (en) Process